Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists

Buy Lab Tests Online

madman

Super Moderator
Abstract

Purpose


In men with prolactinoma treated with dopamine agonists (DA), the extent, timeline, and predictive factors of gonadotropic axis recovery are still unclear.


Methods

We analyzed data of 97 men with a prolactinoma treated with DA (77/97 macroprolactinomas). We excluded patients with primary hypogonadism, surgery <12 months after DA initiation, and patients with tumors <5 mm or prolactin <45 µg/l at diagnosis.


Results

Among the 97 patients, 12 had normal total testosterone (NT group) and 85 had low testosterone at diagnosis (LTgroup). In the NT group, testosterone rose from a mean of 13.5 nmol/l to 17.1nmol/l at 6 months (n=11; p<0.05) then remained stable at 12 months (n=8). In the LT group, testosterone rose from a mean of 5.2 nmol/l to 9.6 nmol/l at 6 months (n=66; p<0.001) and further to 13.1 nmol/l at 12 months (n=40; p<0.001) then remained stable. Recovery from hypogonadism occurred in 43%, 50%, and 54% of patients at 6, 12 and 24 months, respectively (61%, 69 and 69% if prolactin was normal). Factors independently associated with persistent hypogonadism at 12 months were at baseline the presence of visual field deficit and lower testosterone levels, while the most significant independent predictor of persistent hypogonadism at one year was a testosterone level <7.4 nmol/l at 6 months, with 91% sensitivity and 94% specificity.


Conclusion

Testosterone levels recover in a small majority of men with prolactinoma mostly during the first year of DA treatment. However, testosterone replacement could be considered earlier in patients with large and compressive tumors, and in whom testosterone remains below 7.4 nmol/l after 6 months of DA treatment.




Introduction


Men with prolactinoma frequently suffer from hypogonadotropic hypogonadism, manifesting as decreased libido, erectile dysfunction, gynecomastia, weight gain, anemia and bone loss [1]. The symptoms may occur long before the diagnosis of prolactinoma is recognized [2]. Hypogonadism in prolactinoma may be the result of a mechanical compression of the normal pituitary gland or stalk by a macroadenoma and/or the inhibitory effect of excess prolactin on kisspeptin neurons in the hypothalamus [3]. Recovery from hypogonadism is an important objective of any treatment of prolactinoma. The 2023 guidelines from the Pituitary Society recommend reassessing testosterone levels 6 months after treatment initiation and starting exogenous testosterone therapy if frank hypogonadism persists at that time [4]. Because of the lack of enough evidence-based data, both recommendations are however graded as « weak » [4] and do not define at which level of testosterone the start of hormonal substitution is warranted.

The extent and timeline of gonadotropic axis recovery have been studied mostly in small series of less than 50 medically-treated men and showed variable rates of recovery ranging from 27 to 53% [5–9].
In 2022, two reports described hypogonadism recovery in slightly larger cohorts of men with macroprolactinoma treated with dopamine agonists (DA) [10, 11]. In 63 patients with a median tumor size of 2.9 cm, Al Dahmani et al. reported a recovery rate of hypogonadism of 65% mostly within the first 24 months of cabergoline therapy [11]. They observed that patients who recovered had smaller adenoma size, lower prolactin level and higher testosterone at diagnosis, less secondary hypothyroidism and they achieved earlier prolactin normalization. The series reported by Rudman et al [10] was restricted to 58 male patients who had achieved normal prolactin levels on medical therapy. In this setting, predictors of hypogonadism persistence were initial visual field defects, the presence of TSH and ACTH deficiency, and low baseline testosterone (mean: 2.4 nmol/l compared to 5.5 nmol/l in patients with eugonadism recovery). In both series, patients who had surgery were excluded (even if surgery might have occurred after more than 12 months of medical treatment), as well as those with normal testosterone or microadenoma at baseline, thus resulting in the exclusion of a significant subset of patients encountered in real life practice. Two other studies reported the evolution of testosterone levels in prolactinoma patients with normal initial testosterone,which interestingly showed a significant hormone increase of more than 50% with DA therapy [12, 13].

The purpose of our study was to assess the evolution of central hypogonadism during the first two years of treatment with dopamine agonists in a larger and more representative cohort of 97 men, with either micro- or macroprolactinoma, independently of baseline testosterone levels and normalization of prolactin concentrations.




The strengths of our study
include the large and representative cohort of patients (the largest published to date on this subject), the inclusion of microprolactinoma (5–9 mm), the evaluation of cystic components and analysis of the tumor response in parallel to biological response. Limitations include the retrospective design of the study, with missing data for some patients during follow-up, the lack of objective data on sexual function parameters, the lack of free testosterone (index) measurements and the small number of patients who achieved normal prolactin (n=32) at one year, which however reflects real-life practice in our tertiary referral center for resistant or complex cases.




In conclusion, a large majority of men with prolactinoma suffer from hypogonadotropic hypogonadism at diagnosis. Dopamine agonist treatment will lead to a significant increase in testosterone levels, even among those with normal initial testosterone, revealing some degree of initial hypogonadism. Among patients with hypogonadism, recovery of gonadal function was finally observed in 54% of patients, raising to 69% in those who achieved normal prolactin, and this occurs mostly within the first year of medical treatment. We confirm that indicators of mass effect such as tumor size, the presence of a large cystic component, visual field deficit and/or ACTH deficit and low initial testosterone are predictors of persistent hypogonadism, We suggest to consider starting testosterone therapy after 6 months in such patients, especially if total morning testosterone at this time point remains below the cut-off of 7.4 nmol/l. Future studies should strive to prospectively assess both SHBG and free testosterone to better refine our decision making process.
 

Attachments

  • s11102-024-01445-5.pdf
    1.4 MB · Views: 1
Defy Medical TRT clinic doctor
Table 1 Baseline characteristics of the 97 male patients with a prolactinoma and of these same patients divided according to the presence of a normal (NT group; n=12) or low testosterone (< 10.0 nmol/L) at diagnosis (LT group, n=85)
1726619464940.png
 
Fig. 2 Testosterone levels during the first 24 months of dopamine agonist treatment in men with prolactinoma and low initial testosterone concentrations. Green dots represent testosterone levels in patients with normal prolactin after one year of treatment and red dots show testosterone levels in patients with elevated prolactin after one year of treatment. Full lines represent mean testosterone levels. Dotted line represents the inferior limit of normal for testosterone in men (10 nmol/l). ns: non-significant. *** p<0.001. Statistical analysis of the mean testosterone levels for the entire cohort, not restricted to those patients with elevated prolactin at one year (red dots) or not (green dots)
1726619531925.png
 
Fig. 3 Cumulative rate of recovery from hypogonadism in men with prolactinoma treated with dopamine agonists who had achieved normal prolactin or not after 12 months of dopamine agonist therapy
1726619660867.png
 
Table 2 Comparison between patients with recovery of eugonadism or persistent hypogonadotropic hypogonadism after one year of dopamine agonist (DA) treatment
Screenshot (39489).png

Screenshot (39490).png
 
Table 3 Uni- and multivariate logistic regression analysis of factors predicting persistence of hypogonadism at one year
1726619838526.png
 
Beyond Testosterone Book by Nelson Vergel
Table 4 Comparison of series describing hypogonadism recovery in men with prolactinoma during medical treatment
1726619894757.png
 
Buy Lab Tests Online
Defy Medical TRT clinic

Sponsors

bodybuilder test discounted labs
cheap enclomiphene
TRT in UK Balance my hormones
Discounted Labs
Testosterone Doctor Near Me
Testosterone books nelson vergel
nelson vergel coaching for men
Register on ExcelMale.com
Trimix HCG Offer Excelmale
BUY HCG CIALIS

Online statistics

Members online
2
Guests online
8
Total visitors
10

Latest posts

Top